An 82-year-old lady with hypertension and hyperlipidaemia presented with 2 weeks’ history of increasing breathing difficulty. She had flu-like illness 2 weeks ago with some residual dry cough. Physical examination showed low-grade fever of 37.8°C with mildly elevated jugular venous pressure and mild pedal oedema. There was no obvious murmur, and chest auscultation revealed bilateral basal crepitations. Her blood pressure was 130/80 mm Hg. She required oxygen 1 L/min to maintain blood oxygen saturation level (SpO2) of 94 percent.
Chronic obstructive pulmonary disease (COPD) is currently the 10th commonest cause of death in Singapore, with a disease burden of 5.9 percent according to a 2015 population-based survey (EPIC-Asia survey) in Singapore. Pearl Toh spoke with Dr Augustine Tee, chief and senior consultant of the Department of Respiratory and Critical Care Medicine at Changi General Hospital (CGH) in Singapore, on how COPD is often underdetected in the primary care population as symptoms are not specific and diagnosis requires a combination of clinical risk factors, symptoms and spirometry testing.
There are various ear, nose, and throat (ENT) conditions which present to the GP’s clinic. Dr Jason Hwang, an ENT Consultant from the Department of Otolaryngology at Gleneagles Hospital in Singapore, speaks on how the majority of the conditions can be effectively managed at the primary care level seeing that these can be treated medically without the need for surgical intervention.
Lung cancer still poses a challenge in terms of diagnosis and treatment. In many countries in Asia, the condition remains a significant cause of mortality. The prevalence of tuberculosis in the region also confounds this problem, which necessitates a highly efficient means to differentiate these two entities. Electromagnetic navigation bronchoscopy (ENB), a state-of-the-art lung biopsy technique, was recently introduced in Hong Kong, placing the city as a pioneer in its utilization in the region. Dr Chung-Ming Chu, Specialist in Respiratory Medicine in Hong Kong, discusses the role of ENB in diagnosing pulmonary lesions and shares his experience on its use.
This is the case of a 77-year-old man with a history of pulmonary tuberculosis (TB). In September 2015, he was admitted to a regional hospital in Hong Kong due to fever and shortness of breath, and was diagnosed with pneumonia, the fourth episode in his life.
Dengue fever is caused by the dengue virus and borne by the Aedes mosquito. The virus causes flu-like symptoms that generally resolve on their own with supportive care but severe cases require further management and possibly hospitalization. Primary care doctors are frequently the first point of contact for people with dengue fever. Radha Chitale spoke with Dr. Jenny Low, a senior consultant in the Department of Infectious Diseases at Singapore General Hospital, about what they can do for affected patients.
Electronic cigarettes could be one of the biggest public health opportunities of our time, but that depends on who you talk to. They have been shown to be effective in helping smokers quit and many believe them to be much safer than cigarettes. But the debate rages on.
Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Benralizumab reduced asthma exacerbations and improved lung function in patients with severe, eosinophilic asthma, according to results of the SIROCCO* and CALIMA** trials which were presented at the European Respiratory Society (ERS) International Congress 2016 held in London, UK.
New drug applications approved by US FDA as of 16 - 31 Mar 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
New drug applications approved by US FDA as of 1 – 15 April 2015 which
includes New Molecular Entities (NMEs) and new biologics. It does not
include Tentative Approvals. Supplemental approvals may have occurred
since the original approval date.